The brain-derived neurotrophic factor pathway, life stress, and chronic multi-site musculoskeletal pain

Ellen Generaal, PhD¹, Yuri Milaneschi, PhD¹, Rick Jansen, PhD¹, Bernet M Elzinga, PhD²,³, Joost Dekker, PhD¹,⁴ and Brenda WJH Penninx, PhD¹

Abstract

Introduction: Brain-derived neurotrophic factor (BDNF) disturbances and life stress, both independently and in interaction, have been hypothesized to induce chronic pain. We examined whether (a) the BDNF pathway (val⁶⁶met genotype, gene expression, and serum levels), (b) early and recent life stress, and (c) their interaction are associated with the presence and severity of chronic multi-site musculoskeletal pain.

Methods: Cross-sectional data are from 1646 subjects of the Netherlands Study of Depression and Anxiety. The presence and severity of chronic multi-site musculoskeletal pain were determined using the Chronic Pain Grade (CPG) questionnaire. The BDNF val⁶⁶met polymorphism, BDNF gene expression, and BDNF serum levels were measured. Early life stress before the age of 16 was assessed by calculating a childhood trauma index using the Childhood Trauma Interview. Recent life stress was assessed as the number of recent adverse life events using the List of Threatening Events Questionnaire.

Results: Compared to val⁶⁶val, BDNF met carriers more often had chronic pain, whereas no differences were found for BDNF gene expression and serum levels. Higher levels of early and recent stress were both associated with the presence and severity of chronic pain (p < 0.001). No interaction effect was found for the BDNF pathway with life stress in the associations with chronic pain presence and severity.

Conclusions: This study suggests that the BDNF gene marks vulnerability for chronic pain. Although life stress did not alter the impact of BDNF on chronic pain, it seems an independent factor in the onset and persistence of chronic pain.

Keywords
Chronic pain, nerve growth factors, child abuse, life change events

Date received: 17 December 2015; revised: 10 March 2016; accepted: 4 April 2016

Introduction

Chronic musculoskeletal pain, which may even occur without peripheral tissue damage, has been conceptualized as a central sensitization condition in which factors of the central nervous system enhance pain modulation.¹ Central sensitization may occur through disturbances of neurotrophic factors.² Brain-derived neurotrophic factor (BDNF) may be an important pain modulator, as it positively regulates neuronal growth, recovery and development,³ and central and peripheral synaptic plasticity.⁴,⁵ The influence of the BDNF pathway (BDNF genotype, gene-expression, and protein) may be especially prominent when life stress is present, as evidenced by significant BDNF-with-stress interactions found for the onset of depression.⁶–⁸ Such an interaction may also apply to chronic pain as the condition shares similar pathophysiological mechanisms.³

¹Department of Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands
²Institute of Psychology, Leiden University, Leiden, The Netherlands
³Leiden Institute for Brain and Cognition, Leiden, The Netherlands
⁴Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands

Corresponding author:
Ellen Generaal, PO Box 74077, 1070 BB Amsterdam, The Netherlands.
Email: e.generaal@ggzingeest.nl

Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Some studies hypothesized that blocking BDNF in sensory neurons could represent an approach for chronic pain treatment.29 This hypothesis is supported by cross-sectional studies on fibromyalgia, a syndrome with chronic multi-site pain, which consistently showed increased BDNF serum10–12 and plasma13 levels. One study found that increased BDNF expression in the colonic mucosa of chronic abdominal pain patients was correlated with higher pain severity scores compared to controls.14 Other associations between variables (genetic or biomarker) of the BDNF pathway and pain are very inconsistent. A common single-nucleotide polymorphism (SNP) on the BDNF gene is val66met (rs6265), which alters BDNF protein structure by a valine (val) to methionine (met) insertion at codon 66.15 Two studies suggest that BDNF met carriers may be at higher risk for chronic pelvic or abdominal pain,16,17 but this was not found in another study on fibromyalgia.18 However, as the met allele has been found to decrease BDNF secretion,3,15 it would have been expected that val carriers are at a higher risk of chronic pain. So, overall, studies on the BDNF pathway (genotype expression/protein) in chronic pain show inconsistent results, and no earlier studies have examined the BDNF pathway in different levels covering DNA, gene expression, and protein levels. Life stressors may add to the impact of BDNF disturbances on chronic pain. Evidence from cross-sectional and longitudinal studies suggests that early and recent life stress may trigger the development of chronic pain.19–22 Life stressors may have different impact on pain depending on an individual’s genetic risk. In a previous study on depression, BDNF met carriers with a history of childhood trauma showed lower BDNF serum levels compared to met carriers without childhood trauma, whereas this pattern was reversed in the val66val group.23 A gene-environment interaction may also apply to chronic pain. However, previous studies on BDNF in chronic pain (n < 155) are inconsistent, and the interaction of BDNF with life stress has never been tested for chronic pain. Therefore, this cross-sectional study examines the association of (a) the BDNF pathway (val66met genotype, gene expression, and serum level), (b) early and recent stress, and (c) the interaction of the BDNF pathway with early and recent life stress, with the presence and severity of chronic multi-site musculoskeletal pain. We hypothesized that an altered BDNF pathway, higher stress levels, and their combination are associated with the presence and severity of chronic pain.

Methods

Sample

The current cross-sectional study was based on data from the Netherlands Study of Depression and Anxiety (NESDA), an ongoing cohort study conducted among 2981 adults (18–65 years at baseline) from which 94.8% were of North-European ancestry. Subjects were recruited from the general population (n = 564), general practices (n = 1610), and mental health care organizations (n = 807). People with current and remitted psychiatric disorders as well as controls with no psychiatric diagnosis participated. The NESDA study contains a high proportion of subjects with chronic multi-site musculoskeletal pain and provides a unique opportunity for control of relevant variables such as depressive and anxiety disorders. The research protocol was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Center Amsterdam, The Netherlands. Penninx et al.24 provided a detailed description of the NESDA study design and sampling procedures.

For this study, subjects with pain data were selected (n = 2980). From these subjects, 767 persons met criteria for chronic pain and 887 persons were controls (see section below for measurement criteria). Of these subjects, eight persons were excluded because no data were available on BDNF, leaving a total of 1646 subjects. All these subjects had data available on recent stress. Data on early life stress (childhood trauma) were available in 1643 subjects. Data on BDNF val66met genotype were available in 1412 subjects; on BDNF gene expression in 1089 subjects; and on BDNF serum in 1608 subjects. Included subjects (n = 1646) had significantly lower pain scores, were older, were more often male, had less often depression or anxiety, had higher BDNF serum levels, had lower levels of early and recent stress (all \( p < 0.05 \)), but did not differ in BDNF gene expression level and BDNF val66met genotype, compared with with excluded subjects (n = 1335).

Chronic multi-site musculoskeletal pain

Chronic multi-site musculoskeletal pain was defined using the CPG,25 a valid and reliable questionnaire.26,27 The CPG first inquires about the presence of pain in the prior six months in the extremities (joints of the arms, hands, legs, or feet), back, neck, head, abdomen, chest, and the orofacial area (mouth and face).28 The subsequent questions in the CPG refer to the most painful location and inquire (a) days in pain in the prior six months (scale 0–180); (b) pain at this moment (scale 0–10); (c) worst pain in the prior six months (scale 0–10); (d) average pain in the prior six months (scale 0–10); (e) disability days in the prior six months (scale 0–180); (f) disability in daily activities (scale 0–10); (g) disability in spare time, social life, and family activities (scale 0–10); and (h) disability in work (scale 0–10). A total pain intensity score was calculated using questions 2, 3,
and 4 of the CPG; a total pain disability score was calculated using questions 6, 7, and 8 of the CPG (average of the 0–10 ratings of the three questions multiplied by 10 resulting in a 0–100 score). Disability points (seven categories; 0–6) were calculated adding the total disability score (0–100) and the indicated points for disability days (question 5 of the CPG; see Von Korff for details). Five grades were categorized: grade 0 (pain-free, no pain in the prior six months); grade I (low disability (<3 disability points), low intensity (<0.5)); grade II (low disability (<3 disability points), high intensity (>0.5)); grade III (high disability, moderately limiting (3–4 disability points)); and grade IV (high disability, severely limiting (>5 disability points)). Following previous research, we defined chronic multi-site musculoskeletal as grade I, II, III, or IV on the CPG and pain present in the prior six months in the extremities, the back, and the neck. The control group consisted of people with grade 0 (n = 169) or with grade I and pain in at most two locations (n = 713). The remaining subjects not meeting the criteria of the chronic multi-site musculoskeletal pain group or the control group were excluded from the present study (n = 1327). We also refer to the chronic multi-site musculoskeletal pain group as the chronic pain group.

**Brain-derived neurotrophic factor**

**BDNF Val<sup>66</sup>Met genotype.** For detailed description of DNA extraction, quality control, and imputation techniques, see previous studies. BDNF genotyping was performed on multiple chip platforms (including Affymetrix-Perlegen 5.0 and Affymetrix 6.0) in (partially overlapping) different subsets of the total NESDA sample. Quality control was performed within and between chip platforms. Basic quality control steps for subjects included checks for European ancestry, sex inconsistencies, mendelian errors, missing rates, and high genome-wide homozygosity. Genotype data were further checked based on Hardy–Weinberg equilibrium (p = 0.91), minor allele frequencies (MAFs), and call rates. Data were imputed using the 1000 Genomes phase 1 INTEGRATED RELEASE version 3 ALL panel. The Val<sup>166</sup>Met BDNF SNP (rs6265) was typed in some of the panels used for imputation and all post-imputation QC criteria were met. R<sup>2</sup> value for rs6265 (CHR = 11; BP = 27658369) was 0.99, indicating an almost perfect correlation between the imputed genotype and the true underlying genotype. The MAF was 0.21. The current sample (n = 1412) consists of 64% Val<sup>66</sup>Val and 4% Met<sup>66</sup>Met homozygotes, whereas 32% were Val<sup>66</sup>Met heterozygotes. Following previous research, we combined the low-frequency Met<sup>66</sup>Met with Val<sup>66</sup>Met and further refer to this group as “met carriers” (dominant model; Val<sup>66</sup>Val = reference).

**BDNF gene expression.** To assess BDNF gene expression in whole blood, venous blood samples were drawn in the morning (7–10 AM) after an overnight fast in one 7-mL heparin-coated tube (Greiner Bio-One, Monroe, North Carolina). Heparinized whole blood samples were transferred into PAXgene Blood RNA tubes (Qiagen), incubated, and stored at −85°C before RNA isolation. Samples were hybridized to Affymetrix U219 arrays (Affymetrix, Santa Clara, CA) containing 530,467 probes summarized in 49,293 probe sets. Array hybridization, washing, staining, and scanning were carried out in an Affymetrix GeneTitan System per the manufacturer’s protocol. Gene expression data were required to pass standard Affymetrix QC metrics (Affymetrix expression console) before further analysis. We excluded from further analysis probes that did not map uniquely to the hg19 (Genome Reference Consortium Human Build 37) reference genome sequence, as well as probes targeting a messenger RNA (mRNA) molecule resulting from transcription of a DNA sequence containing a single nucleotide polymorphism (based on the dbSNP137 common database). Normalized probe set expression values were obtained using Robust Multi-array Average normalization as implemented in the Affymetrix Power Tools software (version 1.12.0, Affymetrix). No additional gene expression measurement techniques were used to verify our findings. Further details on BDNF gene expression assessment and RNA processing have been described elsewhere. In this study, we calculated the mean BDNF expression across all five probe sets targeting BDNF after adjusting for RNA per plate, position on plate, month and time of blood withdrawal, level of blood hemoglobin, and time between blood withdrawal and RNA extraction.

**BDNF serum.** Serum samples were kept frozen at −85°C for a period between one and four years after which BDNF concentration (ng/mL) was measured using the Emax Immuno Assay system from Promega according to the manufacturer’s protocol. The undiluted serum was acid treated, which in a dilution-dependent way reliably increased the detectable BDNF. Subsequently, serum samples were diluted 100 times and stored again at −85°C for BDNF assay the next day. After dilution, the BDNF concentrations were well within the range of the standard curve. The assay sensitivity threshold was ascertained at 1.56 ng/ml reflecting the minimum level of BDNF in the serum that could be reliably determined. Three samples were below this threshold and therefore excluded from all subsequent analyses. See our previous study for more details on BDNF assessment.
Early life stress was assessed at baseline using the Childhood Trauma Interview (CTI) from The Netherlands Mental Health Survey and Incidence Study. The CTI assesses four domains of trauma before the age of 16 by asking whether the traumatic event occurred (yes/no), and a subsequent question asking how often the event occurred. The domains included emotional neglect (lack of parental attention or support and ignorance of one’s problems and experiences), psychological abuse (being verbally abused, undeserved punishment, subordinated to siblings, and being blackmailed), physical abuse (being kicked or hit with hands or an object, beaten up or physical abuse in any other way), and sexual abuse (being sexually approached against one’s will, meaning being touched or having to touch someone in a sexual way). The CTI yields a score ranging 0 to 8 by adding the frequencies of occurrence (0, absent; 1, once or sometimes; 2, regularly, often or very often). Subsequently, a cumulative index called childhood trauma index was calculated as the sum of experienced number and frequency of childhood trauma for each participant, categorized into five categories (0, 1–2, 3–4, 5–6, and 7–8).

Recent life stress was assessed as the total number of recent adverse life events, which was determined at baseline using the List of Threatening Events Questionnaire. The list assesses 12 life stressors in the year preceding the baseline assessment such as death of a close friend or relative or serious financial problems. We additionally inquired whether subjects experienced any other adverse life event in the past year. Following previous research, this level was set at 0–13) were used in the analyses.

Statistical analyses and covariates

Descriptive baseline characteristics were reported as means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control groups. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group. To examine the differences between groups, means or percentages in the chronic pain and control group.

For analyses of pain severity, fully adjusted linear regression analyses were performed within the chronic pain group (n = 764). The associations of BDNF, early and recent stress, and the interaction of BDNF with early and recent stress were tested with the total pain intensity score and the total pain disability score separately.

Depressive and anxiety disorders have previously been associated with chronic pain. We also showed that BDNF was related to depression and antidepressant medication in our sample. To discard these potential confounding effects, additional analyses were performed adjusting for current (past six months) depressive disorders (major depressive disorder, dysthymia) and anxiety disorders (panic disorder, agoraphobia, generalized anxiety disorder, social phobia) (established with the Composite International Diagnostic Interview: Robins et al.) and frequent use of tricyclic antidepressants (ATC code: N06AA), selective serotonin reuptake inhibitors (N06AB) and other antidepressant medications (N06AF/AG/AX).

For all statistical tests, a probability level of ≤ 5% was regarded as significant. For testing interactions, this level was set at ≤ 10%. The statistical calculations were performed using SPSS V.20 for Windows (IBM, Armonk, NY, USA).

Results

Sample characteristics

Compared to controls, chronic pain subjects had higher pain scores, were significantly older, were more often women, were more often current smokers, had more often a current depressive and/or anxiety disorder, used more frequently antidepressants, and reported more early and recent life stress (Table 1). The BDNF val66met polymorphism, BDNF gene expression, and BDNF serum level showed low and non-significant intercorrelations (Pearson’s r = −.03 to .02, p > .34; data not shown).

The BDNF pathway and the presence and severity of chronic pain

Compared to val66val carriers, BDNF met carriers more often had chronic pain after adjustment for confounders (Table 2). BDNF gene expression and BDNF serum levels were not associated with the presence of chronic pain before and after adjustment for confounders (p > .05).
No significant associations were found for the BDNF variables with neither pain intensity nor pain disability among chronic pain subjects (Table 3). When BDNF expression and serum analyses were additionally adjusted for depression, anxiety, and antidepressants, similar non-significant associations were found with chronic pain presence and severity, with the exception of a significant association for higher BDNF expression with lower pain disability ($\beta = -0.09$, $p = .05$; data not shown).

Previous research has indicated that other confounders may also influence BDNF serum levels. Therefore, we additionally adjusted our fully adjusted model for time of blood withdrawal, time of sample storage, alcohol and food intake, and urbanicity (five categories: <500, 500–1000, 1000–1500, 1500–2500, and >2500 persons/m²). This did not affect our findings for BDNF serum with the presence of chronic pain (OR [95%CI] = 1.00[0.97–1.03], $p = .91$).

According to a previous study, findings for BDNF levels might differ between men and women, and therefore sex-specific associations with chronic pain may exist. To test this, we repeated analyses of the BDNF pathway with the presence of chronic pain while adding BDNF variable x sex interaction terms to the model. No significant interactions were found for any of the variables of the BDNF pathway (all $p > 0.10$).

Table 1. Baseline characteristics.a

|                           | N# | Controls ($n = 882$) | Chronic pain ($n = 764$) | $p^b$ |
|---------------------------|----|---------------------|--------------------------|--------|
| Pain scores               |    |                     |                          |        |
| Days of pain in the prior six months | 1645 | 27.7 (48.7)         | 108.0 (69.5)             | <0.001 |
| Pain intensity            |    | 21.9 (14.7)         | 52.9 (17.9)              | <0.001 |
| Pain disability           |    | 9.8 (13.5)          | 39.7 (25.9)              | <0.001 |
| Sociodemographic factors  |    |                     |                          |        |
| Age, years                |    | 42.0 (13.6)         | 44.7 (12.2)              | <0.001 |
| Women, %                  |    | 56.7                | 73.6                     | <0.001 |
| Lifestyle                 |    |                     |                          |        |
| Smoking, %                |    | 0.02                |                          |        |
| Never smoker              |    | 31.5                | 26.0                     |        |
| Former smoker             |    | 35.7                | 31.3                     |        |
| Current smoker            |    | 32.8                | 42.7                     |        |
| Current affective disorders |   |                     |                          |        |
| Depression and/or anxiety, % |   | 37.6                | 72.6                     | <0.001 |
| Antidepressant medication, % |   | 17.5                | 31.0                     | <0.001 |
| BDNF                      |    |                     |                          |        |
| BDNF Val<sup>66</sup>Met genotype | 1412 |                     |                          | 0.07   |
| Val/Val, %                |    | 66.5                | 61.9                     |        |
| Val/Met, %                |    | 29.0                | 34.7                     |        |
| Met/Met, %                |    | 4.5                 | 3.4                      |        |
| BDNF gene expression      |    | 2.18 (0.1)          | 2.17 (0.1)               | 0.11   |
| BDNF serum level (ng/ml)  |    | 9.1 (3.2)           | 9.3 (3.7)                | 0.26   |
| Early life stress         |    | 0.001               |                          |        |
| Childhood trauma index [0], % |   | 64.7                | 42.8                     |        |
| Childhood trauma index [1–2], % |   | 29.3                | 39.8                     |        |
| Childhood trauma index [3–4], % |   | 6.0                 | 17.3                     |        |
| Recent life stress        |    | 0.001               |                          |        |
| Recent adverse life events [0], % |   | 61.8                | 53.4                     |        |
| Recent adverse life events [1–2], % |   | 33.7                | 38.5                     |        |
| Recent adverse life events [3–6], % |   | 4.5                 | 8.1                      |        |

BDNF: Brain-derived neurotrophic factor.

Values are mean ± SD unless otherwise indicated. N# sample size is $n = 1646$, unless otherwise indicated because of missings on individual measures.

Based on independent-sample t test for continuous variables and $\chi^2$ test for dichotomous and categorical variables. Early and recent life stress are presented as categories for illustrative purposes; continuous variables were used in subsequent analyses.
Recent life stress

Early life stress

structure; adjusted for age, sex, and smoking; adjusted for age and sex.

Based on linear regression analyses, adjusted for age, sex, and population

1 additional event.

are per 1 unit increase in the index; Recent adverse life events: OR are per 1 unit (ng/mL) increase; Childhood trauma index: OR

Gene expression: OR are per 1 unit increase (relative measure); BDNF

disability) of chronic pain (see Tables 2 and 3; all

Early and recent life stress were significantly associated

severity of chronic pain

val66val carriers. BDNF gene expression and serum

This study showed that BDNF met carriers more often had chronic multi-site musculoskeletal pain compared to Val66Val carriers. BDNF gene expression and serum levels were not associated with chronic pain. Higher early and recent stress levels were independently associated with chronic pain presence and severity but did not alter the impact of BDNF on pain.

Our finding that BDNF met carriers are more likely to have chronic pain is in line with previous studies on pain

Table 2. The associations of the BDNF pathway and life stress with the presence of chronic multi-site musculoskeletal pain.

|                | N   | OR [95% CI] | P   |
|----------------|-----|-------------|-----|
| BDNF met carrier genotypea | 1412 | 1.26 [1.01–1.58] | 0.04 |
| BDNF gene expressionb | 1089 | 0.53 [0.21–1.31] | 0.17 |
| BDNF serum levelsb | 1608 | 1.00 [0.97–1.03] | 0.91 |
| Early life stress | | | |
| Childhood trauma index c | 1643 | 1.56 [1.42–1.72] | <0.001 |
| Recent adverse life events c | 1646 | 1.30 [1.17–1.44] | <0.001 |

BDNF: Brain-derived neurotrophic factor.

Note: BDNF genotype: reference group consists of subjects with the Val66Val genotype.

Gene expression: OR are per 1 unit increase (relative measure); BDNF serum: OR are per 1 unit (ng/mL) increase; Childhood trauma index: OR are per 1 unit increase in the index; Recent adverse life events: OR are per 1 additional event.

Based on logistic regression analyses, adjusted for age, sex, and population structure; adjusted for age, sex, and smoking; adjusted for age and sex.

Table 3. The associations of the BDNF pathway and life stress with pain severity in subjects with chronic multi-site musculoskeletal pain.

|                | Pain intensity | Pain disability |                |
|----------------|---------------|----------------|---------------|
|                | N  | Beta | p   | N  | Beta | p   |
| BDNF met carrier genotypea | 654 | 0.04 | 0.36 | −0.03 | 0.50 |
| BDNF gene expressionb | 534 | −0.03 | 0.44 | −0.08 | 0.06 |
| BDNF serum levelsb | 740 | 0.04 | 0.31 | −0.03 | 0.40 |
| Early life stress | | | | | |
| Childhood trauma index c | 761 | 0.13 | <0.001 | 0.19 | <0.001 |
| Recent adverse life events c | 764 | 0.15 | <0.001 | 0.14 | <0.001 |

BDNF: Brain-derived neurotrophic factor.

Note: BDNF genotype: reference group consists of subjects with the Val66Val genotype.

Based on linear regression analyses, adjusted for age, sex, and population structure; adjusted for age, sex, and smoking; adjusted for age and sex.

Early and recent life stress and the presence and severity of chronic pain

Early and recent life stress were significantly associated with both the presence and the severity (intensity and disability) of chronic pain (see Tables 2 and 3; all

p < 0.001). Additionally adjusting for depression, anxiety, and antidepressants showed somewhat lower, however significant, odds ratios for both early stress (OR [95%CI] = 1.37[1.24–1.52], p < 0.001) and recent stress (OR [95%CI] = 1.20[1.07–1.34], p = 0.001) with chronic pain presence. Similarly, the associations with pain severity were somewhat weaker, however, remained statistically significant (early stress: β = 0.10, p = 0.004 with intensity and β = 0.17, p < 0.001 with disability; recent stress: β = 0.13, p < 0.001 with intensity and β = 0.12, p = 0.001 with disability).

The interaction of BDNF with life stress and the presence and severity of chronic pain

No significant interaction effect of the BDNF pathway with life stress was found in the associations with chronic pain presence and severity (see Tables 4 and 5). Two from a total of 18 tested interaction terms appeared statistically significant (p < 0.10; Table 5). Additionally adjusting the analyses for depression, anxiety, and antidepressants did not affect these findings.

Discussion

This study showed that BDNF met carriers more often had chronic multi-site musculoskeletal pain compared to Val66Val carriers. BDNF gene expression and serum levels were not associated with chronic pain. Higher early and recent stress levels were independently associated with chronic pain presence and severity but did not alter the impact of BDNF on pain.

Our finding that BDNF met carriers are more likely to have chronic pain is in line with previous studies on pain

Table 4. The interaction of the BDNF pathway with life stress in the association with the presence of chronic multi-site musculoskeletal pain.

|                | N   | P   |
|----------------|-----|-----|
| BDNF × early life stress | | |
| BDNF genotype × traumaa | 1409 | 0.53 |
| BDNF expression × traumaa | 1087 | 0.74 |
| BDNF serum × traumaa | 1605 | 0.24 |
| BDNF × recent life stress | | |
| BDNF genotype × eventsa | 1412 | 0.11 |
| BDNF expression × eventsa | 1089 | 0.19 |
| BDNF serum × eventsa | 1608 | 0.64 |

BDNF: Brain-derived neurotrophic factor.

Note: BDNF genotype: met carriers vs. Val66Val (reference group); trauma = childhood trauma index; events = total number of recent adverse life events.

Based on logistic regression analyses, adjusted for age, sex, and population structure; adjusted for age, sex, and smoking.
Table 5. The interaction of the BDNF pathway with life stress in the association with the severity of chronic multi-site musculoskeletal pain.

| BDNF × early life stress | Pain intensity | Pain disability |
|-------------------------|----------------|----------------|
|                         | N   | p   | p   |
| BDNF genotype × trauma  | 651 | 0.24| 0.92|
| BDNF expression × trauma| 532 | 0.82| 0.37|
| BDNF serum × trauma     | 737 | 0.36| 0.82|
| BDNF × recent life stress|    |     |     |
| BDNF genotype × events  | 654 | 0.19| 0.05|
| BDNF expression × events| 534 | 0.73| 0.49|
| BDNF serum × events     | 740 | 0.06| 0.16|

BDNF: Brain-derived neurotrophic factor.
Note: BDNF genotype: met carriers vs. Val66Val (reference group); trauma = childhood trauma index; events = total number of recent adverse life events.
Based on linear regression analyses, *adjusted for age, sex, and population structure; †adjusted for age, sex, and smoking.

There are some methodological considerations to our study. First, we only assessed the Val66met variant, whereas the genetic risk of chronic pain may be increased by polygenic variation. Studies examining genome-wide associations or a polygenic risk score for chronic multi-site pain may be useful. Nonetheless, this study was driven by a well-founded hypothesis that BDNF plays a crucial role in pain modulation and neural plasticity.4,5 Second, we measured BDNF on one day, whereas future research could examine BDNF levels based on several measurements. Nevertheless, we have likely compensated the potentially limited reliability of our BDNF assessment with our large sample size. Third, our classification of chronic pain was pain in the extremities, the back, and the neck in the prior six months. Previous studies mostly examined chronic widespread pain, axial and bilateral pain above and below the waist according to the American College of Rheumatology criteria.54 We may have included some patients with milder pain due to our “less stringent” definition. However, the majority of multi-site pain patients which do not fulfil the “widespread” criteria still suffer from severe limitations, high pain intensity, and significant psychological distress.55 It might hence be useful to set broader parameters for studying mechanisms underlying chronic pain. Fourth, we did not take subjects’ appraisals of the life events into account. Future studies could examine whether findings are different when including appraisal of the past experiences. Fifth, our sample contains a high proportion of subjects with depression and anxiety. Nonetheless, these disorders co-occur frequently with chronic pain, and our design did allow us to adjust for their potential confounding effects. This large-scale study was the first to examine the complete BDNF pathway in relation to chronic pain, while testing potential interactions with life stress.

Our data provide evidence that the BDNF Val66met polymorphism marks vulnerability for chronic pain. Life stress does not seem to increase the impact of BDNF on pain. Instead, life stress may directly trigger the onset or persistence chronic pain.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

1. Phillips K and Clauw DJ. Central pain mechanisms in the rheumatic diseases: future directions. Arthritis Rheum 2013; 65: 291–302.
2. Obata K and Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res 2006; 55: 1–10.
3. Maletic V and Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci 2009; 14: 5291–5338.
4. Merighi A, Salio C, Ghirri A, et al. BDNF as a pain modulator. Prog Neurobiol 2008; 85: 297–317.
5. Gatt JM, Nemeroff CB, Dobson-Stone C, et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 2009; 14: 681–695.
6. Molenendijk ML, van Tol MJ, Penninx BW, et al. BDNF Val66met affects hippocampal volume and emotion-related hippocampal memory activity. Transl Psychiatry 2012; 2: e74.
7. Nijp J, Meeus M, Versijpt J, et al. Brain-derived neurotrophic factor as a driving force behind neuroplasticity in neuropathic and central sensitization pain: a new therapeutic target? Expert Opin Ther Targets 2015; 19: 565–576.
8. Noguera B, Korallus C and Gutenbrunner C. Serum level of brain-derived neurotrophic factor in fibromyalgia syndrome correlates with depression but not anxiety. Neurochem Int 2013; 62: 281–286.
9. Laske C, Stransky E, Eschweiler GW, et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatr Res 2007; 41: 600–605.
10. Zanette SA, Dussan-Sarria JA, Souza A, et al. Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol Pain 2014; 10: 46.
11. Haas L, Portela LV, Bohmer AE, et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010; 35: 830–834.
12. Yu YB, Zuo XL, Zhao QJ, et al. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut 2012; 61: 685–694.
13. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257–269.
14. Lee LC, Tu CH, Chen LF, et al. Association of brain-derived neurotrophic factor gene Val66Met polymorphism with primary dysmenorrhea. PLoS One 2014; 9: e112766.
15. Reddy SY, Rasmussen NA, Fourie NH, et al. Sleep quality, BDNF genotype and gene expression in individuals with chronic abdominal pain. BMC Med Genomics 2014; 7: 61.
16. Xiao Y, Russell JJ and Liu YG. A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein. Rheumatol Int 2012; 32: 2479–2485.
17. Anderberg BM, Marteinsdottir I, Theorell T, et al. The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry 2000; 15: 295–301.
18. Lampe A, Doering S, Rumpold G, et al. Chronic pain syndromes and their relation to childhood abuse and stressful life events. J Psychosom Res 2003; 54: 361–367.
19. Jones GT, Power C and Macfarlane GJ. Adverse events in childhood and chronic widespread pain in adult life: results from the 1958 British Birth Cohort Study. Pain 2009; 143: 92–96.
20. Generaal E, Vogelzangs N, Macfarlane GJ, et al. Biological stress systems, adverse life events and the onset of chronic multisite musculoskeletal pain: a 6-year cohort study. Ann Rheum Dis. Epub ahead of print 22 April 2015. DOI: 10.1136/annrheumdis-2014-206741.
21. Elzinga BM, Molenendijk ML, Oude Voshaar RC, et al. The impact of childhood abuse and recent stress on serum brain-derived neurotrophic factor and the moderating role of BDNF Val66Met. Psychopharmacology(Berl) 2011; 214: 319–328.
22. Penninx BW, Beeckman AT, Smit JH, et al. The Netherlands Study of Depression and Anxiety (NEDA): rationale, objectives and methods. Int J Methods Psychiatr Res 2008; 17: 121–140.
23. Von Korff M, Ormel J, Keefe FJ, et al. Grading the severity of chronic pain. Pain 1992; 50: 133–149.
24. Elliott AM, Smith BH, Smith WC, et al. Changes in chronic pain severity over time: the Chronic Pain Grade as a valid measure. Pain 2000; 88: 303–308.
25. Smith BH, Penny KI, Purves AM, et al. The Chronic Pain Grade questionnaire: validation and reliability in postal research. Pain 1997; 71: 141–147.
26. Von Korff M. Epidemiologic and survey methods: chronic pain assessment. In: Turk DC and Melzack R (eds) Handbook of pain assessment, 2nd ed. New York: Guilford Press, 2001, pp.603–618.
27. Generaal E, Vogelzangs N, Macfarlane GJ, et al. Reduced hypothalamic-pituitary-adrenal axis activity in chronic multi-site musculoskeletal pain: partly masked by depressive and anxiety disorders. BMC Musculoskeletal Disorders 2014; 15: 227.
28. Generaal E, Vogelzangs N, Macfarlane GJ, et al. Basal inflammation and innate immune response in chronic multisite musculoskeletal pain. Pain 2014; 155: 1605–1612.
29. Nivard MG, Mbarek H, Hottenga JJ, et al. Further confirmation of the association between anxiety and CTNND2: replication in humans. Genes Brain Behav 2014; 13: 195–201.
32. Boomsma DI, Willemsen G, Sullivan PF, et al. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. *Eur J Hum Genet* 2008; 16: 335–342.

33. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature* 2012; 491: 56–65.

34. Colzato LS, Van der Does AJ, Kouwenhoven C, et al. BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults. *Psychoneuroendocrinology* 2011; 36: 1562–1569.

35. Jansen R, Batista S, Brooks AI, et al. Sex differences in the human peripheral blood transcriptome. *BMC Genomics* 2014; 15: 33.

36. Wright FA, Sullivan PF, Brooks AI, et al. Heritability and genomics of gene expression in peripheral blood. *Nat Genet* 2014; 46: 430–437.

37. Bus BA, Molendijk ML, Penninx BJ, et al. Determinants of serum brain-derived neurotrophic factor. *Psychoneuroendocrinology* 2011; 36: 228–239.

38. de Graaf R, Bijl RV, ten Have M, et al. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. *J Affect Disord* 2004; 82: 461–467.

39. Brugha T, Bebbington P, Tennant C, et al. The list of threatening experiences: a subset of 12 life event categories with considerable long-term contextual threat. *Psychol Med* 1985; 15: 189–194.

40. Abdellaoui A, Hottenga JJ, de Knijff P, et al. Population structure, migration, and diversifying selection in the Netherlands. *Eur J Hum Genet* 2013; 21: 1277–1285.

41. Gerrits MM, van Marwijk HW, van Oppen P, et al. Longitudinal association between pain, and depression and anxiety over four years. *J Psychosom Res* 2015; 78: 64–70.

42. Molendijk ML, Bus BA, Spinhoen P, et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. *Mol Psychiatry* 2011; 16: 1088–1095.

43. Robins LN, Wing J, Wittchen HU, et al. The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry* 1988; 45: 1069–1077.

44. Bus BA, Arias-Vasquez A, Franke B, et al. Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males. *Neuropsychobiology* 2012; 65: 183–187. DOI:10.1159/000336997.

45. Molendijk ML, Bus BA, Spinhoen P, et al. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume—a genuine effect or a winners curse? *Am J Med Genet B Neuropsychiatr Genet* 2012; 159B: 731–740.

46. Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet* 2013; 45: 1238–1243.

47. Yu H, Zhang Z, Shi Y, et al. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. *J Clin Psychiatry* 2008; 69: 1104–1111.

48. Fujimura H, Altar CA, Chen R, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. *Thromb Haemost* 2002; 87: 728–734.

49. Sullivan PF, Fan C and Perou CM. Evaluating the comparability of gene expression in blood and brain. *Am J Med Genet B Neuropsychiatr Genet* 2006; 141B: 261–268.

50. Molendijk ML, Haffmans JP, Bus BA, et al. Serum BDNF concentrations show strong seasonal variation and correlations with the amount of ambient sunlight. *PLoS One* 2012; 7: e48046.

51. Eyre H and Baune BT. Neuroplastic changes in depression: a role for the immune system. *Psychoneuroendocrinology* 2012; 37: 1397–1416.

52. Naert G, Ixart G, Tapia-Arancibia L, et al. Continuous i.c.v. infusion of brain-derived neurotrophic factor modifies hypothalamic-pituitary-adrenal axis activity, locomotor activity and body temperature rhythms in adult male rats. *Neuroscience* 2006; 139: 779–789.

53. Duclot F and Kabbaj M. Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. *J Exp Biol* 2015; 218: 21–31.

54. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. *Arthritis Rheum* 1990; 33: 160–172.

55. Carnes D, Parsons S, Ashby D, et al. Chronic musculoskeletal pain rarely presents in a single body site: results from a UK population study. *Rheumatology (Oxford)* 2007; 46: 1168–1170.